EX-23.1 6 exhibit231consentofernstyo.htm EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)Registration Statement (Form S-3 No. 333-276942) of Autolus Therapeutics plc,

(2)Registration Statement (Form S-8 No. 333-226457) pertaining to the Autolus Limited 2017 Share Option Plan and Autolus Therapeutics plc 2018 Equity Incentive Plan, and

(3)Registration statement (Form F-3 No. 333-264304) of Autolus Therapeutics plc and in the related Prospectus,

(4)Registration statement (Form F-3 No. 333-264650) of Autolus Therapeutics plc and in the related Prospectus,

(5)Registration Statement (Form S-8 Nos. 333-273776 and 333-275301) pertaining to the Autolus Therapeutics plc 2018 Equity Incentive Plan,

(6)Registration Statement (Form S-3 No. 333-278320) of Autolus Therapeutics plc,

(7)Registration Statement (Form S-8 No. 333-283229) pertaining to the Autolus Therapeutics plc 2018 Equity Incentive Plan;

of our report dated March 20, 2025, with respect to the consolidated financial statements of Autolus Therapeutics plc included in this Annual Report (Form 10-K) of Autolus Therapeutics plc for the year ended December 31, 2024.

/s/ Ernst & Young LLP

Reading, United Kingdom

March 20, 2025